Jigar Raythatha, Principal

Mr. Raythatha joined Red Abbey Venture Partners in 2005 as a Kauffman Fellow (Class 10) and is currently a Principal. He led the firm’s recent investment in Stromedix, a company that was formed around a molecule acquired from Biogen Idec, Inc., and serves as a BOD observer at the company.

Prior to joining Red Abbey, Mr. Raythatha spent four years at Biogen, Inc. (now Biogen Idec, Inc.) in business development and new product commercialization. There, he was responsible for leading cross-functional due diligence teams and helped negotiate several strategic transactions. Most notably, Mr. Raythatha helped complete a joint development collaboration with ICOS Corporation for small molecule LFA-1 inhibitors and an oncology joint development collaboration with IDEC Pharmaceuticals, Inc, which laid the groundwork for the merger of the companies. Additionally, Mr. Raythatha led the commercial strategy for six R&D programs in the areas of oncology, autoimmune disease and fibrosis and was part of the team tasked with developing Biogen’s oncology strategy. Mr. Raythatha also worked for A.T. Kearney as a management consultant and completed internships with Pfizer, Inc., HSS Ventures, Columbia Science & Technology Ventures and Carrot Capital.

Mr. Raythatha holds a BA in Molecular Biology & Biochemistry and Economics from Rutgers College and an MBA from Columbia Business School. He is currently attending Johns Hopkins University where he is completing an MS in Biotechnology.

*****
Contact Jigar: jraythatha@redabbey.com